474 related articles for article (PubMed ID: 9515759)
1. Azathioprine: state of the art in inflammatory bowel disease.
Sandborn WJ
Scand J Gastroenterol Suppl; 1998; 225():92-9. PubMed ID: 9515759
[TBL] [Abstract][Full Text] [Related]
2. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.
Prefontaine E; Macdonald JK; Sutherland LR
Cochrane Database Syst Rev; 2009 Oct; (4):CD000545. PubMed ID: 19821270
[TBL] [Abstract][Full Text] [Related]
3. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.
Prefontaine E; Macdonald JK; Sutherland LR
Cochrane Database Syst Rev; 2010 Jun; (6):CD000545. PubMed ID: 20556747
[TBL] [Abstract][Full Text] [Related]
4. Azathioprine: an update on clinical efficacy and safety in inflammatory bowel disease.
Lamers CB; Griffioen G; van Hogezand RA; Veenendaal RA
Scand J Gastroenterol Suppl; 1999; 230():111-5. PubMed ID: 10499471
[TBL] [Abstract][Full Text] [Related]
5. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
6. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease.
Prefontaine E; Sutherland LR; Macdonald JK; Cepoiu M
Cochrane Database Syst Rev; 2009 Jan; (1):CD000067. PubMed ID: 19160175
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine.
Egan LJ; Sandborn WJ; Tremaine WJ
Am J Gastroenterol; 1998 Mar; 93(3):442-8. PubMed ID: 9517654
[TBL] [Abstract][Full Text] [Related]
8. Methotrexate for induction of remission in refractory Crohn's disease.
McDonald JW; Tsoulis DJ; Macdonald JK; Feagan BG
Cochrane Database Syst Rev; 2012 Dec; 12():CD003459. PubMed ID: 23235598
[TBL] [Abstract][Full Text] [Related]
9. Azathioprine or 6-mercaptopurine for inflammatory bowel disease: do risks outweigh benefits?
Su CG; Stein RB; Lewis JD; Lichtenstein GR
Dig Liver Dis; 2000; 32(6):518-31. PubMed ID: 11057928
[TBL] [Abstract][Full Text] [Related]
10. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease.
Belaiche J; Desager JP; Horsmans Y; Louis E
Scand J Gastroenterol; 2001 Jan; 36(1):71-6. PubMed ID: 11218242
[TBL] [Abstract][Full Text] [Related]
12. [Azathioprine treatment of Crohn disease].
Thomsen MK; Vilien M; Gerner CU
Ugeskr Laeger; 2000 Jan; 162(3):323-6. PubMed ID: 10680466
[TBL] [Abstract][Full Text] [Related]
13. 5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine.
Hande S; Wilson-Rich N; Bousvaros A; Zholudev A; Maurer R; Banks P; Makrauer F; Reddy S; Burakoff R; Friedman S
Inflamm Bowel Dis; 2006 Apr; 12(4):251-7. PubMed ID: 16633046
[TBL] [Abstract][Full Text] [Related]
14. Optimum duration of treatment with 6-mercaptopurine for Crohn's disease.
Kim PS; Zlatanic J; Korelitz BI; Gleim GW
Am J Gastroenterol; 1999 Nov; 94(11):3254-7. PubMed ID: 10566725
[TBL] [Abstract][Full Text] [Related]
15. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
Wong DR; Pierik M; Seinen ML; van Bodegraven AA; Gilissen LP; Bus P; Bakker JA; Masclee AA; Neef C; Engels LG; Hooymans PM
J Crohns Colitis; 2014 Feb; 8(2):120-8. PubMed ID: 23932783
[TBL] [Abstract][Full Text] [Related]
16. Leukopenia predicts remission in patients with inflammatory bowel disease and Behcet's disease on thiopurine maintenance.
Park MS; Kim DH; Kim DH; Park SJ; Hong SP; Kim TI; Kim WH; Cheon JH
Dig Dis Sci; 2015 Jan; 60(1):195-204. PubMed ID: 25239495
[TBL] [Abstract][Full Text] [Related]
17. Medical therapy of inflammatory bowel disease for the 21st century.
Robinson M
Eur J Surg Suppl; 1998; (582):90-8. PubMed ID: 10029372
[TBL] [Abstract][Full Text] [Related]
18. Protocol for a multinational risk-stratified randomised controlled trial in paediatric Crohn's disease: methotrexate versus azathioprine or adalimumab for maintaining remission in patients at low or high risk for aggressive disease course.
Harris RE; Aloi M; de Ridder L; Croft NM; Koletzko S; Levine A; Turner D; Veereman G; Neyt M; Bigot L; Ruemmele FM; Russell RK;
BMJ Open; 2020 Jul; 10(7):e034892. PubMed ID: 32611737
[TBL] [Abstract][Full Text] [Related]
19. Increased dosing requirements for 6-mercaptopurine and azathioprine in inflammatory bowel disease patients six years and younger.
Grossman AB; Noble AJ; Mamula P; Baldassano RN
Inflamm Bowel Dis; 2008 Jun; 14(6):750-5. PubMed ID: 18266236
[TBL] [Abstract][Full Text] [Related]
20. Relationship between 6-mercaptopurine dose and 6-thioguanine nucleotide levels in patients with inflammatory bowel disease.
Morales A; Salguti S; Miao CL; Lewis JD
Inflamm Bowel Dis; 2007 Apr; 13(4):380-5. PubMed ID: 17206711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]